Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
Oladapo Yeku(Harvard University), Renier J. Brentjens(Roswell Park Comprehensive Cancer Center)
Cited by 397
Related Papers
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
|Nature Reviews Clinical Oncology|2019|1.4k
CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date
|Blood|2016|398
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
|Blood|2019|277
IL-18–secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models
|Journal of Clinical Investigation|2023|165
TYRP1 directed CAR T cells control tumor progression in preclinical melanoma models
|Molecular Therapy Oncology|2024|9